Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.09
LZAGY's Cash to Debt is ranked lower than
94% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. LZAGY: 0.09 )
Ranked among companies with meaningful Cash to Debt only.
LZAGY' s 10-Year Cash to Debt Range
Min: 0.07  Med: 0.17 Max: No Debt
Current: 0.09
Equity to Asset 0.33
LZAGY's Equity to Asset is ranked lower than
83% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. LZAGY: 0.33 )
Ranked among companies with meaningful Equity to Asset only.
LZAGY' s 10-Year Equity to Asset Range
Min: 0.3  Med: 0.33 Max: 0.5
Current: 0.33
0.3
0.5
F-Score: 7
Z-Score: 2.11
M-Score: -2.68
WACC vs ROIC
6.96%
8.55%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.68
LZAGY's Operating margin (%) is ranked higher than
76% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. LZAGY: 10.68 )
Ranked among companies with meaningful Operating margin (%) only.
LZAGY' s 10-Year Operating margin (%) Range
Min: 7.06  Med: 11.62 Max: 15.02
Current: 10.68
7.06
15.02
Net-margin (%) 5.56
LZAGY's Net-margin (%) is ranked higher than
71% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.06 vs. LZAGY: 5.56 )
Ranked among companies with meaningful Net-margin (%) only.
LZAGY' s 10-Year Net-margin (%) Range
Min: 2.43  Med: 6.51 Max: 14.27
Current: 5.56
2.43
14.27
ROE (%) 10.12
LZAGY's ROE (%) is ranked higher than
72% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.27 vs. LZAGY: 10.12 )
Ranked among companies with meaningful ROE (%) only.
LZAGY' s 10-Year ROE (%) Range
Min: 4.11  Med: 11.75 Max: 22.52
Current: 10.12
4.11
22.52
ROA (%) 3.27
LZAGY's ROA (%) is ranked higher than
66% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.44 vs. LZAGY: 3.27 )
Ranked among companies with meaningful ROA (%) only.
LZAGY' s 10-Year ROA (%) Range
Min: 1.3  Med: 4.30 Max: 7.45
Current: 3.27
1.3
7.45
ROC (Joel Greenblatt) (%) 27.08
LZAGY's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. LZAGY: 27.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LZAGY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 7.69  Med: 12.82 Max: 46.01
Current: 27.08
7.69
46.01
Revenue Growth (3Y)(%) 10.30
LZAGY's Revenue Growth (3Y)(%) is ranked higher than
71% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. LZAGY: 10.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LZAGY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -5.5  Med: 6.05 Max: 12.8
Current: 10.3
-5.5
12.8
EBITDA Growth (3Y)(%) 9.80
LZAGY's EBITDA Growth (3Y)(%) is ranked higher than
68% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. LZAGY: 9.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LZAGY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -12.2  Med: 7.95 Max: 48.1
Current: 9.8
-12.2
48.1
EPS Growth (3Y)(%) 15.20
LZAGY's EPS Growth (3Y)(%) is ranked higher than
77% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. LZAGY: 15.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LZAGY' s 10-Year EPS Growth (3Y)(%) Range
Min: -32.9  Med: -1.25 Max: 29.6
Current: 15.2
-32.9
29.6
» LZAGY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with LZAGY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 29.14
LZAGY's P/E(ttm) is ranked higher than
53% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.70 vs. LZAGY: 29.14 )
Ranked among companies with meaningful P/E(ttm) only.
LZAGY' s 10-Year P/E(ttm) Range
Min: 8.61  Med: 21.64 Max: 69.7
Current: 29.14
8.61
69.7
Forward P/E 1.73
LZAGY's Forward P/E is ranked higher than
66% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.33 vs. LZAGY: 1.73 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 28.70
LZAGY's PE(NRI) is ranked higher than
53% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.80 vs. LZAGY: 28.70 )
Ranked among companies with meaningful PE(NRI) only.
LZAGY' s 10-Year PE(NRI) Range
Min: 8.61  Med: 20.84 Max: 69.7
Current: 28.7
8.61
69.7
P/B 3.50
LZAGY's P/B is ranked lower than
53% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. LZAGY: 3.50 )
Ranked among companies with meaningful P/B only.
LZAGY' s 10-Year P/B Range
Min: 0.74  Med: 1.99 Max: 3.97
Current: 3.5
0.74
3.97
P/S 1.83
LZAGY's P/S is ranked higher than
68% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. LZAGY: 1.83 )
Ranked among companies with meaningful P/S only.
LZAGY' s 10-Year P/S Range
Min: 0.63  Med: 1.47 Max: 2.58
Current: 1.83
0.63
2.58
PFCF 22.74
LZAGY's PFCF is ranked higher than
66% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.00 vs. LZAGY: 22.74 )
Ranked among companies with meaningful PFCF only.
LZAGY' s 10-Year PFCF Range
Min: 6.28  Med: 19.21 Max: 210.54
Current: 22.74
6.28
210.54
POCF 14.28
LZAGY's POCF is ranked higher than
75% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.49 vs. LZAGY: 14.28 )
Ranked among companies with meaningful POCF only.
LZAGY' s 10-Year POCF Range
Min: 3.47  Med: 10.00 Max: 36.17
Current: 14.28
3.47
36.17
EV-to-EBIT 21.00
LZAGY's EV-to-EBIT is ranked higher than
51% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.91 vs. LZAGY: 21.00 )
Ranked among companies with meaningful EV-to-EBIT only.
LZAGY' s 10-Year EV-to-EBIT Range
Min: 9.9  Med: 19.50 Max: 32.6
Current: 21
9.9
32.6
PEG 7.97
LZAGY's PEG is ranked lower than
83% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. LZAGY: 7.97 )
Ranked among companies with meaningful PEG only.
LZAGY' s 10-Year PEG Range
Min: 0.25  Med: 1.28 Max: 86.05
Current: 7.97
0.25
86.05
Shiller P/E 35.92
LZAGY's Shiller P/E is ranked lower than
62% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.93 vs. LZAGY: 35.92 )
Ranked among companies with meaningful Shiller P/E only.
LZAGY' s 10-Year Shiller P/E Range
Min: 6.25  Med: 13.88 Max: 38.32
Current: 35.92
6.25
38.32
Current Ratio 1.21
LZAGY's Current Ratio is ranked lower than
83% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. LZAGY: 1.21 )
Ranked among companies with meaningful Current Ratio only.
LZAGY' s 10-Year Current Ratio Range
Min: 0.97  Med: 1.27 Max: 1.84
Current: 1.21
0.97
1.84
Quick Ratio 0.63
LZAGY's Quick Ratio is ranked lower than
92% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. LZAGY: 0.63 )
Ranked among companies with meaningful Quick Ratio only.
LZAGY' s 10-Year Quick Ratio Range
Min: 0.62  Med: 0.80 Max: 1.09
Current: 0.63
0.62
1.09
Days Inventory 55.78
LZAGY's Days Inventory is ranked higher than
60% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.06 vs. LZAGY: 55.78 )
Ranked among companies with meaningful Days Inventory only.
LZAGY' s 10-Year Days Inventory Range
Min: 95  Med: 107.93 Max: 123.17
Current: 55.78
95
123.17
Days Sales Outstanding 60.64
LZAGY's Days Sales Outstanding is ranked higher than
56% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. LZAGY: 60.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
LZAGY' s 10-Year Days Sales Outstanding Range
Min: 6.55  Med: 62.37 Max: 94.23
Current: 60.64
6.55
94.23

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.87
LZAGY's Dividend Yield is ranked higher than
73% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.46 vs. LZAGY: 1.87 )
Ranked among companies with meaningful Dividend Yield only.
LZAGY' s 10-Year Dividend Yield Range
Min: 0.96  Med: 2.23 Max: 6.38
Current: 1.87
0.96
6.38
Dividend Payout 0.61
LZAGY's Dividend Payout is ranked lower than
70% of the 50 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.33 vs. LZAGY: 0.61 )
Ranked among companies with meaningful Dividend Payout only.
LZAGY' s 10-Year Dividend Payout Range
Min: 0.22  Med: 0.45 Max: 1.29
Current: 0.61
0.22
1.29
Yield on cost (5-Year) 2.38
LZAGY's Yield on cost (5-Year) is ranked higher than
65% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. LZAGY: 2.38 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
LZAGY' s 10-Year Yield on cost (5-Year) Range
Min: 1.21  Med: 2.82 Max: 8.07
Current: 2.38
1.21
8.07
Share Buyback Rate -0.20
LZAGY's Share Buyback Rate is ranked higher than
81% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.70 vs. LZAGY: -0.20 )
Ranked among companies with meaningful Share Buyback Rate only.
LZAGY' s 10-Year Share Buyback Rate Range
Min: 0.6  Med: -0.35 Max: -3.4
Current: -0.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 3.39
LZAGY's Price/Tangible Book is ranked higher than
62% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.24 vs. LZAGY: 3.39 )
Ranked among companies with meaningful Price/Tangible Book only.
LZAGY' s 10-Year Price/Tangible Book Range
Min: 2.27  Med: 8.48 Max: 47.54
Current: 3.39
2.27
47.54
Price/Projected FCF 1.79
LZAGY's Price/Projected FCF is ranked higher than
54% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. LZAGY: 1.79 )
Ranked among companies with meaningful Price/Projected FCF only.
LZAGY' s 10-Year Price/Projected FCF Range
Min: 1.58  Med: 2.26 Max: 5.86
Current: 1.79
1.58
5.86
Price/DCF (Earnings Based) 5.13
LZAGY's Price/DCF (Earnings Based) is ranked lower than
93% of the 15 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. LZAGY: 5.13 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.37
LZAGY's Price/Median PS Value is ranked lower than
74% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. LZAGY: 1.37 )
Ranked among companies with meaningful Price/Median PS Value only.
LZAGY' s 10-Year Price/Median PS Value Range
Min: 0.45  Med: 0.98 Max: 1.55
Current: 1.37
0.45
1.55
Price/Graham Number 8.56
LZAGY's Price/Graham Number is ranked lower than
92% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. LZAGY: 8.56 )
Ranked among companies with meaningful Price/Graham Number only.
LZAGY' s 10-Year Price/Graham Number Range
Min: 1.17  Med: 2.71 Max: 7.21
Current: 8.56
1.17
7.21
Earnings Yield (Greenblatt) (%) 4.74
LZAGY's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. LZAGY: 4.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LZAGY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.1  Med: 5.10 Max: 10.1
Current: 4.74
3.1
10.1
Forward Rate of Return (Yacktman) (%) 5.83
LZAGY's Forward Rate of Return (Yacktman) (%) is ranked lower than
63% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.53 vs. LZAGY: 5.83 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
LZAGY' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -13.2  Med: 5.90 Max: 38.4
Current: 5.83
-13.2
38.4

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 3,314 3,441
EPS($) 5.69 6.65
EPS without NRI($) 5.69 6.65

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:LONN.Switzerland, LO3.Germany, O6Z.Singapore, 0QNO.UK,
Lonza Group AG was founded in 1897. The Company is a suppliers of biopharmaceuticals to the Pharma&Biotech and Specialty Ingredient markets. Its products and services range from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens, from the manufacture of vitamin B compounds and organic personal care ingredients to agricultural services and products. The Company operates in two market segments: The Lonza Pharma&Biotech and The Lonza Specialty Ingredients. The Lonza Pharma&Biotech (LPB) market segment clusters all of its offerings for pharmaceutical markets, with strong Lonza positions in Custom Development, Custom Manufacturing and Bioscience Solutions. The Lonza Specialty Ingredients (LSI) market segment includes consumer-oriented offerings, with Consumer Care encompassing its Personal Care & Preservation, Nutrition and Hygiene offerings.
» More Articles for LZAGY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Lonza Prices CHF 325 Million Dual Tranche Straight Bonds Aug 20 2015
Lonza Acquires Research-Focused Chemical Company Zelam Based in New Zealand Aug 03 2015
Lonza First-Half Profit Beats Estimates, Prompting Asset Review Jul 22 2015
Lonza’s Re-Positioning Continues to Drive Improving Results Jul 22 2015
AMBS: Amarantus Closes Cutanogen Acquisition Jul 15 2015
Lonza upgraded by Kepler Jul 07 2015
Lonza to Expand the Availability of the RAFT™ 3D Cell Culture System Jul 07 2015
Lonza Announces Additional Long-Term Agreement with Alexion Jul 02 2015
Lonza Offers Disinfectants to Combat Norovirus on Cruise Ships Jun 25 2015
Octane and Lonza Announce Exclusive Collaboration to Evaluate Groundbreaking Autologous Cell Therapy... Jun 23 2015
Lonza Announces QC Insider™ Toolbox for Endotoxin Expertise at Your Fingertips™ Jun 22 2015
Finding Growth Stocks in Europe Jun 17 2015
Edited Transcript of PTLA earnings conference call or presentation 6-May-15 8:30pm GMT Jun 16 2015
Lonza to Expand Viral Therapy Business with Planned Construction of New Facility in Houston, TX Jun 16 2015
Lonza Introduces New L7™ PBMC Reprogramming Bundle for the Simple, Rapid and Reliable Generation... Jun 11 2015
Lonza Consumer Care Expert to Speak at World of Wipes® International Conference Jun 04 2015
Lonza to Present New Technologies and Products for Advancing Stem Cell Research and Discovery at... May 26 2015
Lonza Announces Additional Speakers for Next Month’s 1st Global Endotoxin Testing Summit May 21 2015
Lonza Introduces CytoSMART™ System for Walk-Away Live Cell Imaging May 05 2015
Lonza Reports Robust Q1 Performance and Sound Growth Prospects Until 2018 Apr 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK